查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
单纯疱疹病毒治疗市场 - 全球市场规模、份额、趋势分析、机会和预测报告，2019-2029
市场调查报告书
商品编码
1319312

单纯疱疹病毒治疗市场 - 全球市场规模、份额、趋势分析、机会和预测报告，2019-2029

Herpes Simplex Virus Treatment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Drug Type ; By Distribution Channel ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

到 2029 年，全球单纯疱疹病毒 (HSV) 治疗市场规模将达到 21.7 亿美元

由于HSV检测和治疗方法市场的不断发展以及HSV感染患病率的上升，全球单纯疱疹病毒（HSV）治疗市场正在蓬勃发展。

领先的战略咨询和市场研究公司 BlueWeave Consulting 最近估计，2022 年全球单纯疱疹病毒 (HSV) 治疗市场规模为 17.3 亿美元。 BlueWeave 预测，在 2023-2029 年预测期内，全球单纯疱疹病毒 (HSV) 治疗市场规模将以 3.83% 的年复合成长率增长，到 2029 年达到 21.7 亿美元。全球单纯疱疹病毒（HSV）治疗市场的主要增长促进因素包括疱疹感染患病率的增加、对可用治疗方案的认识提高、对有效治疗的需求增加等。抗病毒药物的更多采用和新型治疗方法的开发进一步促进了市场增长。单纯疱疹是一种广泛传播的疱疹病毒株，罹患世界上很大一部分人口，估计罹患约 37 亿人。这种高度传染性的感染可以通过多种体液传播，包括唾液、阴道分泌物和精液，并且通常在感染者不知情的情况下传播。在预测期内，COVID-19 患者（包括接种疫苗的患者）中人类疱疹病毒的溶血性再激活也显着增加。然而，最常用的疱疹药物的常见副作用预计将抑制全球单纯疱疹病毒（HSV）治疗市场的增长。

该报告的详细分析提供了有关全球单纯疱疹病毒（HSV）治疗市场的增长潜力、未来趋势和统计数据的信息。它还涵盖了推动市场总规模预测的因素。该报告致力于提供全球单纯疱疹病毒（HSV）治疗市场的最新技术趋势以及行业见解，帮助决策者做出明智的战略决策。它还分析了市场的增长促进因素、挑战和竞争力。

目录

第1章研究框架

第2章执行摘要

第3章全球单纯疱疹病毒 (HSV) 治疗市场洞察

  • 行业价值链分析
  • DROC分析
    • 增长促进因素
      • 单纯疱疹病毒感染的传播
      • HSV 检测和药物开发的增加
    • 抑制因素
      • 最常用的疱疹药物的常见副作用
    • 机会
      • 增加研发活动
      • 新兴经济体的高增长潜力
    • 任务
      • 与单纯疱疹病毒相关的耻辱
  • 技术进步/最新发展
  • 监管框架
  • 波特五力分析
  • 价格分析：2019-2022年全球汽车存储器

第4章全球单纯疱疹病毒（HSV）治疗市场概述

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 按类型
      • 单纯疱疹病毒1型感染
      • 单纯疱疹病毒2型感染
    • 按药物类型
      • 阿昔洛韦
      • 伐昔洛韦
      • 泛昔洛韦
    • 按分销渠道
      • 医院药房
      • 药店和零售药店
      • 在线提供商
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第5章北美单纯疱疹病毒（HSV）治疗市场

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按药物类型
    • 按分销渠道
    • 按国家/地区
      • 我们
      • 加拿大

第6章欧洲单纯疱疹病毒（HSV）治疗市场

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按药物类型
    • 按分销渠道
    • 按国家/地区
      • 德国
      • 英国
      • 意大利
      • 法国
      • 西班牙
      • 荷兰
      • 其他欧洲国家

第7章亚太地区单纯疱疹病毒（HSV）治疗市场

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按药物类型
    • 按分销渠道
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳大利亚和新西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 菲律宾
      • 越南
      • 亚太地区其他地区

第8章拉丁美洲单纯疱疹病毒（HSV）治疗市场

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按药物类型
    • 按分销渠道
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 哥伦比亚
      • 拉丁美洲其他地区

第9章中东和非洲单纯疱疹病毒（HSV）治疗市场

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按药物类型
    • 按分销渠道
    • 按国家/地区
      • 沙特阿拉伯
      • 阿拉伯联合酋长国
      • 卡塔尔
      • 科威特
      • 南非
      • 尼日利亚
      • 阿尔及利亚
      • MEA 的其余部分

第10章竞争格局

  • 主要公司及其产品列表
  • 2022年全球单纯疱疹病毒（HSV）治疗产品企业市场份额分析
  • 通过运行参数进行竞争基准测试
  • 主要战略发展（合併、收购、合作伙伴关係等）

第11章新型冠状病毒病（COVID-19）对全球单纯疱疹病毒（HSV）治疗市场的影响

第12章公司简介（公司简介、财务矩阵、竞争格局、关键人才、主要竞争、联繫地址、战略展望和SWOT分析）

  • Abbott Laboratories
  • Pfizer, Inc.
  • Amneal Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Fresenius SE & Co. KGaA
  • Novartis AG
  • Viatris, Inc.
  • Emcure Pharmaceuticals Limited
  • Other Prominent Players

第13章关键战略建议

第14章调查方法

  • 定性研究
    • 初级和次级研究
  • 定量研究
  • 市场细分和数据三角测量
    • 二次调查
    • 初步调查
  • 主要调查受访者的地区分布
  • 假设和限制
简介目录
Product Code: BWC23615

Global Herpes Simplex Virus (HSV) Treatment Market Size Set to Touch USD 2.17 Billion by 2029.

Global herpes simplex virus (HSV) treatment market is flourishing because of an increasing development of HSV testing and medications and rising prevalence of HSV infections.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global herpes simplex virus (HSV) treatment market size at USD 1.73 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global herpes simplex virus (HSV) treatment market size to grow at a CAGR of 3.83% reaching a value of USD 2.17 billion by 2029. Major growth drivers for the global herpes simplex virus (HSV) treatment market include an increasing prevalence of herpes infections, rising awareness about available treatment options, and the growing demand for effective therapies. Increasing adoption of antiviral drugs and the development of novel treatment approaches are further contributing to market growth. Herpes simplex, a widespread strain of the herpes virus, affects a substantial portion of the global population, with approximately 3.7 billion individuals estimated to be impacted. This highly contagious infection can be transmitted through various bodily fluids such as saliva, vaginal secretions, or semen, often without the carrier's knowledge. Also, there has been a noticeable rise in human herpesvirus lytic reactivation among COVID-19 patients, including those who have received vaccinations, during the forecast period. However, prevalent side effects of most used herpes medications are anticipated to restrain the global herpes simplex virus (HSV) treatment market growth.

Global Herpes Simplex Virus (HSV) Treatment Market - Overview:

The global herpes simplex virus (HSV) treatment market refers to the collective market for pharmaceutical products, therapies, and interventions used in the management and treatment of herpes infections caused by the herpes simplex virus. This market encompasses various treatment options, including antiviral medications, topical creams, vaccines, and other therapeutic approaches aimed at reducing the severity of outbreaks, alleviating symptoms, and suppressing viral replication. The market is driven by the increasing prevalence of herpes infections globally, the growing demand for effective treatment options, and ongoing research and development efforts to improve therapeutic outcomes.

Impact of COVID-19 on Global Herpes Simplex Virus (HSV) Treatment Market:

COVID-19 pandemic had a dual impact on the global herpes simplex virus (HSV) treatment market. On the one hand, the increased focus on healthcare and hygiene practices raised awareness about the importance of managing infectious diseases like HSV. It increased the demand for HSV treatments. On the other hand, the diversion of healthcare resources and disruption of supply chains as the pandemic posed challenges for accessing and delivering HSV treatments. Also, the prioritization of COVID-19-related research and development temporarily slowed down advancements in HSV treatment options. The overall impact of COVID-19 on the global herpes simplex virus (HSV) treatment market remains complex and may vary across regions.

Global Herpes Simplex Virus (HSV) Treatment Market - By Drug Type:

Based on drug type, the global herpes simplex virus (HSV) treatment market is divided into Acyclovir, Valacyclovir, and Famciclovir segments. Valacyclovir segment held the highest share in the global herpes simplex virus treatment market during 2022. This can be attributed to its cost-effectiveness, wide availability, and remarkable efficacy in inhibiting the replication of the herpes virus within the body, thus effectively managing the symptoms associated with herpes outbreaks. Valacyclovir is particularly favored for its superior absorption rate compared to acyclovir, making it a preferred choice for treating cold sores, as oral acyclovir is susceptible to rapid breakdown by the liver. Also, a study published in the American Journal of Ophthalmology has demonstrated the comparable effectiveness of a 500 mg valacyclovir dose in preventing the recurrence of HSV eye disease to that of an 800 mg acyclovir dose. Meanwhile, the acyclovir segment is expected to witness fastest growth during the forecast period. This can be attributed to the widespread acceptance of acyclovir as the industry benchmark for the treatment of herpes infections. Also, the market's growth is fueled by the introduction of over-the-counter drugs for infection treatment.

Competitive Landscape:

Major players operating in the global herpes simplex virus treatment market include: Abbott Laboratories, Pfizer Inc., Amneal Pharmaceuticals Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd, Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris Inc., and Emcure Pharmaceuticals Limited. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Herpes Simplex Virus (HSV) Treatment Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Herpes Simplex Virus (HSV) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Herpes Simplex Virus (HSV) Treatment Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of herpes simplex virus infections
      • 3.2.1.2. Rising development of HSV testing and medications
    • 3.2.2. Restraints
      • 3.2.2.1. Prevalent side effects of most used herpes medications
    • 3.2.3. Opportunities
      • 3.2.3.1. Increase in R&D activities
      • 3.2.3.2. High growth potential in developing economies
    • 3.2.4. Challenges
      • 3.2.4.1. Stigma associated with herpes simplex virus
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry
  • 3.6. Price Point Analysis: Global Automotive Memory, 2019-2022

4. Global Herpes Simplex Virus (HSV) Treatment Market Overview

  • 4.1. Market Size & Forecast by Value, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Herpes simplex virus-1 infection
      • 4.2.1.2. Herpes simplex virus-2 infection
    • 4.2.2. By Drug Type
      • 4.2.2.1. Acyclovir
      • 4.2.2.2. Valacyclovir
      • 4.2.2.3. Famciclovir
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital pharmacies
      • 4.2.3.2. Drug store and retail pharmacies
      • 4.2.3.3. Online providers
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Herpes Simplex Virus (HSV) Treatment Market

  • 5.1. Market Size & Forecast by Value, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Drug Type
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Type
      • 5.2.4.1.2. By Drug Type
      • 5.2.4.1.3. By Distribution Channel
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Type
      • 5.2.4.2.2. By Drug Type
      • 5.2.4.2.3. By Distribution Channel

6. Europe Herpes Simplex Virus (HSV) Treatment Market

  • 6.1. Market Size & Forecast by Value, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Type
      • 6.2.4.1.2. By Drug Type
      • 6.2.4.1.3. By Distribution Channel
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Type
      • 6.2.4.2.2. By Drug Type
      • 6.2.4.2.3. By Distribution Channel
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Type
      • 6.2.4.3.2. By Drug Type
      • 6.2.4.3.3. By Distribution Channel
      • 6.2.4.4. France
      • 6.2.4.4.1. By Type
      • 6.2.4.4.2. By Drug Type
      • 6.2.4.4.3. By Distribution Channel
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Type
      • 6.2.4.5.2. By Drug Type
      • 6.2.4.5.3. By Distribution Channel
      • 6.2.4.6. The Netherlands
      • 6.2.4.6.1. By Type
      • 6.2.4.6.2. By Drug Type
      • 6.2.4.6.3. By Distribution Channel
      • 6.2.4.7. Rest of Europe
      • 6.2.4.7.1. By Type
      • 6.2.4.7.2. By Drug Type
      • 6.2.4.7.3. By Distribution Channel

7. Asia-Pacific Herpes Simplex Virus (HSV) Treatment Market

  • 7.1. Market Size & Forecast by Value, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Type
      • 7.2.4.1.2. By Drug Type
      • 7.2.4.1.3. By Distribution Channel
      • 7.2.4.2. India
      • 7.2.4.2.1. By Type
      • 7.2.4.2.2. By Drug Type
      • 7.2.4.2.3. By Distribution Channel
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Type
      • 7.2.4.3.2. By Drug Type
      • 7.2.4.3.3. By Distribution Channel
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Type
      • 7.2.4.4.2. By Drug Type
      • 7.2.4.4.3. By Distribution Channel
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Type
      • 7.2.4.5.2. By Drug Type
      • 7.2.4.5.3. By Distribution Channel
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Type
      • 7.2.4.6.2. By Drug Type
      • 7.2.4.6.3. By Distribution Channel
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Type
      • 7.2.4.7.2. By Drug Type
      • 7.2.4.7.3. By Distribution Channel
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Type
      • 7.2.4.8.2. By Drug Type
      • 7.2.4.8.3. By Distribution Channel
      • 7.2.4.9. Philippines
      • 7.2.4.9.1. By Type
      • 7.2.4.9.2. By Drug Type
      • 7.2.4.9.3. By Distribution Channel
      • 7.2.4.10. Vietnam
      • 7.2.4.10.1. By Type
      • 7.2.4.10.2. By Drug Type
      • 7.2.4.10.3. By Distribution Channel
      • 7.2.4.11. Rest of APAC
      • 7.2.4.11.1. By Type
      • 7.2.4.11.2. By Drug Type
      • 7.2.4.11.3. By Distribution Channel

8. Latin America Herpes Simplex Virus (HSV) Treatment Market

  • 8.1. Market Size & Forecast by Value, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Type
      • 8.2.4.1.2. By Drug Type
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Type
      • 8.2.4.2.2. By Drug Type
      • 8.2.4.2.3. By Distribution Channel
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Type
      • 8.2.4.3.2. By Drug Type
      • 8.2.4.3.3. By Distribution Channel
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Type
      • 8.2.4.4.2. By Drug Type
      • 8.2.4.4.3. By Distribution Channel
      • 8.2.4.5. Colombia
      • 8.2.4.5.1. By Type
      • 8.2.4.5.2. By Drug Type
      • 8.2.4.5.3. By Distribution Channel
      • 8.2.4.6. Rest of LATAM
      • 8.2.4.6.1. By Type
      • 8.2.4.6.2. By Drug Type
      • 8.2.4.6.3. By Distribution Channel

9. Middle East & Africa Herpes Simplex Virus (HSV) Treatment Market

  • 9.1. Market Size & Forecast by Value, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Type
      • 9.2.4.1.2. By Drug Type
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Type
      • 9.2.4.2.2. By Drug Type
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Type
      • 9.2.4.3.2. By Drug Type
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Type
      • 9.2.4.4.2. By Drug Type
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Type
      • 9.2.4.5.2. By Drug Type
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Type
      • 9.2.4.6.2. By Drug Type
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Type
      • 9.2.4.7.2. By Drug Type
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Type
      • 9.2.4.8.2. By Drug Type
      • 9.2.4.8.3. By Distribution Channel

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Herpes Simplex Virus (HSV) Treatment Products Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Herpes Simplex Virus (HSV) Treatment Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)

  • 12.1. Abbott Laboratories
  • 12.2. Pfizer, Inc.
  • 12.3. Amneal Pharmaceuticals, Inc.
  • 12.4. GlaxoSmithKline PLC
  • 12.5. Teva Pharmaceuticals Industries Ltd.
  • 12.6. Glenmark Pharmaceuticals Limited
  • 12.7. Fresenius SE & Co. KGaA
  • 12.8. Novartis AG
  • 12.9. Viatris, Inc.
  • 12.10. Emcure Pharmaceuticals Limited
  • 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumption & Limitation